Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges

Front Cover
Peter Irving, MD, MRCP, Corey A. Siegel, David Rampton, Fergus Shanahan
John Wiley & Sons, Aug 24, 2011 - Medical - 288 pages
The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice.

In this new edition, 75% of the “dilemmas” are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn’s disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking.

Each of the 57 evidence-based chapters contains clear learning points, addresses different topics, and provides sound guidance on subjects ranging from optimizing current management through to special management problems and novel treatments.

This book is suitable for all medical professionals involved in the care of patients with IBD: established and trainee gastroenterologists, colorectal surgeons, pathologists, radiologists, specialist nurses, pharmacists, dieticians and counselors.

 

Selected pages

Contents

Preface
IBD in different ethnic groups same or different?
How does the risk of infection influence management
Chapter
Treatment of IBDinpatients with HCV Treatment of viral hepatitiseffect of interferon on
treatment
Prebiotics and synbiotics panacea or placebo
Do we reallyneed to vaccinate allpatients with IBD?
Useandabuse ofbiologicsin pregnancy
The risks of immunomodulators and biologics what
Avoiding drug interactions
Isthere
Safety of HSCT in Crohns disease
Chapter
Issurgery
disease

Biomarkers in IBDmyth or marvel?
Surveillance colonoscopy in UC what is the best
minimizing radiation exposure
What is theclinicaland observational evidence?
Steroids in Crohns disease
Thioguanine nucleotide measurement nonadherent
What shouldbedone? Conclusions
Optimizing use of methotrexate
Conclusions
Areall antiTNF agents the same?
One drug or two do patients on biologics need
How do we identify patients needing early aggressive
What is the role of biologics inUC?
Which extraintestinal manifestations of IBD respond
ofcervical cancer in thiopurinetreated
Combined cohorts
Dealing with pouchitis
Mucosal healing in IBD does it matter?
Got milk? Medication use and nursing in women with
So where is all the cancer?
What should patients with IBD eat?
Doesstress matter?
IBD Standards will they enhance patient care?
using quality measures to enhance care
Inflammatory bowel disease what to tell your
Transitioning from pediatric to adult care
Index
Copyright

Other editions - View all

Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges
Peter Irving, MD, MRCP,Corey A. Siegel,David Rampton,Fergus Shanahan
Limited preview - 2011

Common terms and phrases

6­mercaptopurine active adalimumab antibodies anti­TNF agents anti­TNF therapy arthritis associated azathioprine biologic cell certolizumab certolizumab pegol cervical cancer chronic Clin Gastroenterol Hepatol clinical cohort colectomy colonic colonoscopy colorectal combination therapy complications corticosteroids Crohn's disease Crohn's disease CD cyclosporine diagnosis dose double­blind drugs dysplasia efficacy endoscopic etal exposure fistula follow­up Gastroenterology hepatitis Hospital IBD patients immune immunomodulators increased risk induce infection Inflamm Bowel inflammatory bowel disease infliximab inpatients intestinal inthe laparoscopic surgery LEARNING POINTS lesions long­term lymphoma maintenance malignancy mesalamine meta­analysis metabolite methotrexate mucosal healing necrosis factor nutrition ofthe oral outcomes patients with Crohn's patients with IBD patients with inflammatory patientswith pediatric perianal placebo placebo­controlled population­based postoperative potential pouchitis probiotics radiation randomized rates reduced refractory remission reported resection response risk factors riskof Sandborn WJ skin cancer steroids studies sulfasalazine surveillance symptoms tacrolimus therapeutic thiopurines transplantation treatment trial tumor ulcerative colitis vaccination

About the author (2011)

Dr Corey Siegel, Director, Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Gastroenterology and Hepatology, Lebanon, NH, USA.

Dr Peter Irving, Consultant Gastroenterologist, Guy's and St Thomas' Hospital London.

Prof David Rampton, Professor of Clinical Gastroenterology, Barts and The London, London.

Prof Fergus Shanahan, Professor and Chairman, Department of Medicine/Director of Alimentary Pharmabiotic Centre, University College Cork, Ireland.

Bibliographic information

TitleClinical Dilemmas in Inflammatory Bowel Disease: New Challenges
EditorsPeter Irving, MD, MRCP, Corey A. Siegel, David Rampton, Fergus Shanahan
Edition2
PublisherJohn Wiley & Sons, 2011
ISBN144434255X, 9781444342550
Length288 pages
Subjects › 

Medical / Gastroenterology
Medical / General
  
Export CitationBiBTeX EndNote RefMan